Humacyte (HUMA) Shares Outstanding (Diluted Average) (2020 - 2025)

Humacyte (HUMA) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $158.2 million in Q4 2025.

• Shares Outstanding (Diluted Average) for Q4 2025 came in at $158.2 million, up 33.49% year-over-year; the trailing twelve-month figure through Dec 2025 was $158.2 million (up 33.49% YoY), and the FY2025 annual result was $158.2 million, up 33.49% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $158.2 million in Q4 2025 per HUMA's latest filing, from $148.5 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $158.2 million in Q4 2025 and troughed at $5.9 million in Q1 2021.
• A 5-year average of $99.1 million and a median of $103.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) jumped 1658.91% in 2022, then decreased 0.54% in 2023.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $40.0 million in 2021, then jumped by 157.82% to $103.1 million in 2022, then rose by 0.36% to $103.4 million in 2023, then advanced by 14.56% to $118.5 million in 2024, then soared by 33.49% to $158.2 million in 2025.
• Business Quant data shows HUMA's Shares Outstanding (Diluted Average) at $158.2 million in Q4 2025, $148.5 million in Q3 2025, and $155.4 million in Q2 2025.